Biomet Deal Opens Door for PE Buyers
Executive Summary
A $10.9 billion bid by a consortium of private equity investors to buy Biomet raises questions about whether this is the first of many such deals or an outlier.
You may also be interested in...
Devices Pique Private Equity's Interest
The spate of recent carve-outs from Boston Scientific has private equity and venture capital investors hungry for similar deals across the industry. But device companies don't seem to be serving much up.
Devices Pique Private Equity's Interest
The spate of recent carve-outs from Boston Scientific has private equity and venture capital investors hungry for similar deals across the industry. But device companies don't seem to be serving much up.
Trends for the New Year: Can Medtech Build on the Success of 2007?
Looking back at 2007, the performance of the medical industry seems strong, from blockbuster M&A to a better-than-expected result of a years-long DOJ investigation into the orthopedics industry. Even Boston Scientific seemed finally to be turning the corner. Drug-eluting stents (DES) got a second chance as data presented from several trials showed better mortality than with bare-metal stents. Venture capitalists poured even more money into device start-ups, both young and old. The confidence shown by venture investors was, not surprisingly, reflected in an IPO market that appeared to continue its recent rebound. But there are also some concerns: company consolidation, increased safety concerns and litigation revolving around physician-manufacturer relationships are causing some to wonder how long the foundation on which the industry's strong showing of recent years can sustain.